Retinal Vein Occlusion Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Retinal Vein Occlusion Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The retinal vein occlusion market size has grown rapidly in recent years. It will grow from $13.79 billion in 2023 to $15.43 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to aging population, advancements in diagnostic imaging, pharmaceutical developments, increased diabetes prevalence.

The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to innovative treatment approaches, telemedicine and remote monitoring, personalized medicine, regulatory approvals. Major trends in the forecast period include non-invasive treatment options, gene therapy breakthroughs, patient-centric care, digital health tools.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13058&type=smp

Market Segmentation:
The main types of retinal vein occlusion are branch retinal artery occlusion and central retinal vein occlusion. Branch retinal artery occlusion refers to a condition characterized by decreased arterial blood flow to a branch of the central retinal artery, leading to ischemic damage in the affected area of the retina, which is treated with ocular hypotensive drugs such as topical timolol or IV or oral acetazolamide. These conditions are categorized into non-ischemic and ischemic types, which are diagnosed by optical coherence tomography, fundoscopic examination and fluorescein angiography. The treatment approach includes antivascular endothelial growth factor, corticosteroid drugs and laser retinal photocoagulation provided by end users such as hospitals and clinics, research and academic centers and others.

Major Driver - Rising Prevalence Of Eye Disorders Fuels Growth In The Ocular Drug Delivery Market
An increase in the prevalence of eye disorders is expected to propel the growth of the ocular drug delivery market going forward. Eye disorders refer to a wide range of conditions that affect the eyes, vision, or the structures surrounding the eyes. The increased incidence of renal vein occlusion drives growth in the renal vein occlusion market, fostering demand for innovative diagnostics and treatments to address this condition. For instance, in March 2023, according to the World Health Organization, a Switzerland-based United Nations agency, globally, 2.2 billion people will have a near- or far-sighted impairment, according to estimates, cataracts (94 million) and uncorrected refractive problems (88.4 million) are the main causes of visual loss or impaired vision. In addition, glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases) and trachoma (2 million cases) are the other common causes of vision loss. Therefore, the increasing prevalence of eye disorders will drive the retinal vein occlusion market.

Competitive Landscape:
Major players in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Allergan PLC, Regeneron Pharmaceuticals Inc., Biogen Idec Inc., Vertex Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co. Ltd., Lumenis Ltd., Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co. Ltd., IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd., Adverum Biotechnologies Inc., Avik Pharmaceutical Limited (Avik), Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

Top Trend - Pioneering Innovations In The Retinal Vein Occlusion Market To Gain Competitive Advantage
Companies operating in the retinal vein occlusion market are adopting novel approaches to enhance patient care and treatment outcomes and sustain their position in the market. Advancements in drug development can increase treatment options for RVO, providing more targeted and effective treatment. For instance, in April 2023, Iridex Corporation, a US-based ophthalmic medical technology company, launched the next-generation Iridex PASCAL. The brand-new platform offers a cutting-edge technology package that combines rapid and accurate pattern scanning abilities, endpoint management technology, a pattern scanning laser trabeculoplasty and micropulse technology in a more compact, ergonomically designed integrated laser platform to provide individualized care to patients with retinal disease.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Retinal Vein Occlusion Market Characteristics
3. Retinal Vein Occlusion Market Trends And Strategies
4. Retinal Vein Occlusion Market - Macro Economic Scenario
5. Retinal Vein Occlusion Market Size And Growth
…..
27. Retinal Vein Occlusion Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.